| Name | Stem Cell Therapy (Autologous or Allogeneic). Includes mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, or umbilical cord sources. |
| Uses | Elective regenerative medicine therapy for musculoskeletal conditions, joint pain, aesthetic applications, and general wellness. Not FDA-approved for systemic disease treatment. |
| Route Of Administration | Intravenous (IV), intra-articular (joint injection), intradermal, subcutaneous, or localized injection. |
| Frequency Of Use | Maximum of once every 3-6 months for joint injections; once every 6-12 months for systemic IV therapy. Individualized based on patient response. |
| Concentration(s) | Typically 1-10 million cells per mL for injectables; IV formulations may range from 10-100 million cells per infusion. |
| Maximum Dosage (Day, Wk) | IV: 100 million cells per session; Joint injections: 10 million cells per joint per session; no more than 2 joints treated per session. |
| Contraindications | Active malignancy, active infection, pregnancy, autoimmune flare-ups, uncontrolled chronic diseases, history of anaphylaxis to stem cell components, clotting disorders. |
| Possible Side Effects | Injection site pain, swelling, transient fever, headache, fatigue, rare risk of immune reaction or clot formation. |
| Compatibility With Other Treatments/Drugs | Safe with PRP therapy; avoid concurrent use with immunosuppressants, anticoagulants, or corticosteroids. |
| Allergies | Potential allergy to preservatives, DMSO (if used for cryopreserved cells). Perform allergy testing if history of hypersensitivity exists. |
| Administration Time | IV infusion: 45-90 minutes; Joint injections: 15-30 minutes per site; Intradermal/subcutaneous: 10-15 minutes. |
| Dosing/Settings | IV: 10-100 million cells diluted in 250-500 mL saline or lactated Ringer’s; Joint: 2-10 million cells per mL; Intradermal: 0.1-0.5 million cells per site. |
| Test Spot Requirement | Recommended for intradermal applications; observe for 24 hours for hypersensitivity before full treatment. |
| Pre-Treatment Guidelines | Discontinue NSAIDs, corticosteroids, and anticoagulants 5-7 days prior. Ensure adequate hydration. Obtain informed consent. |
| Provider Clearance Guidelines | Patients with chronic conditions require physician clearance. Obtain recent lab work (CBC, CMP, inflammatory markers if needed). |
| Pre-Treatment Screening Workflow | 1. Obtain patient history; 2. Assess contraindications; 3. Perform physical exam; 4. Obtain informed consent; 5. Discuss realistic expectations. |
| What To Do If Adverse Reaction Occurs | For mild reactions: observe and provide supportive care. For severe reactions: administer antihistamines or epinephrine (if anaphylaxis), call emergency services if needed. |
| Clinic Implementation Guidelines | Verify patient ID, prep injection site using sterile technique, ensure proper stem cell thawing (if frozen), adhere to aseptic protocols. |
| Photographic Documentation Protocol | Pre/post-treatment photos for joint and aesthetic applications; use standardized lighting and angles. |
| Post-Treatment Care | Avoid NSAIDs for 2 weeks, maintain hydration, gentle movement for joint treatments, follow up in 1-2 weeks. |
| Additional Documentation Requirements | Detailed treatment log including lot number of stem cells, informed consent form, pre/post-treatment assessments. |